Luminescent porous silicon nanoparticles for targeted delivery and immunization
The disclosure relates to immunizing agents and devices.
1. A composition comprising:
(a) a biocompatible porous silicon micro- or nanostructure that exhibits luminescence when irradiated with light;
(b) an antigen presenting cell (APC) stimulating agent adsorbed to the micro- or nanostructure; and
(c) an antigen loaded into the pores of the porous micro- or nanostructure.
2. The composition of claim 1 , wherein at least a portion of the silicon micro- or nanostructure comprises a silicon dioxide material.
3. The composition of claim 1 , wherein the micro- or nanostructure comprises a particulate size of between about 5 nm and 100 μm.
4. The composition of claim 1 , wherein the biocompatible porous micro- or nanostructure is non-toxic.
5. The composition of claim 1 , further comprising a targeting moiety linked to the micro- or nanostructure surface.
6. The composition of claim 5 , wherein the targeting moiety is a receptor ligand, receptor or antibody.
7. The composition of claim 5 , wherein the targeting moiety further comprises stimulating activity that induces APC immunoactivity.
8. The composition of claim 1 , wherein the antigen is a cancer cell antigen.
9. The composition of claim 8 , wherein the cancer cell antigen is selected from the group consisting of KS 1/4 pan-carcinoma antigen; ovarian carcinoma antigen (CA125), prostatic acid phosphate; prostate specific antigen; melanoma-associated antigen p97; melanoma antigen gp75; high molecular weight melanoma antigen and prostate specific membrane antigen.
10. The composition of claim 1 , wherein the antigen is a viral antigen.
11. The composition of claim 10 , wherein the viral antigen is an antigenic epitope from hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, arbovirus, hantavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus, human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II) or a combination thereof.
12. The composition of claim 1 , wherein the antigen is a bacterial antigen.
13. The composition of claim 1 , wherein the APC stimulating agent is a CD40 agonist.
14. The composition of claim 13 , wherein the CD40 agonist is an agonist antibody selected from FGK45, HM40-3, 3/23, 5C3, Mab-89, BE-1, EA5, and M3 monoclonal antibodies.
15. The composition of claim 1 , wherein the composition induces an immunogenic activity that is at least 1 fold greater than if the same antigen is presented in the absence of the composition.
16. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
17. A composition comprising:
a biocompatible porous micro- or nanostructure comprising silicon, a plurality of pores and wherein the structure has an emission spectrum whose wavelength of maximum intensity is about 500 to about 1000 nm and an excitation spectrum whose wavelength of maximum intensity is between about 290 to about 700 nm by single photon excitation or about 600 to about 1200 nm by two photon excitation;
an antigen within the pores; and
a targeting moiety linked or bound to the structure for targeting to an antigen presenting cell and activating the antigen presenting cells.
18. A method of evoking an immune response to an antigen in a subject comprising contacting the subject with a composition of claim 1 .
19. A composition comprising:
a biocompatible porous micro- or nanostructure comprising silicon, a plurality of pores and wherein the structure has an emission spectrum whose wavelength of maximum intensity is about 500 to about 1000 nm and an excitation spectrum whose wavelength of maximum intensity is between about 290 to about 700 nm by single photon excitation or about 600 to about 1200 nm by two photon excitation;
an antigen within the pores; and
a coating or encapsulating polymeric material that coats or encapsulates the biocompatible porous micro- or nanostructure, wherein the coating or encapsulating polymeric material further comprises an immune system activating agent.